Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch M J, Kallioniemi O P, Sauter G
Institute for Pathology and Clinics for Urology, University of Basel, Basel, Switzerland.
Am J Pathol. 1999 Apr;154(4):981-6. doi: 10.1016/S0002-9440(10)65349-7.
Many genes and signaling pathways are involved in renal cell carcinoma (RCC) development. However, genetic tumor markers have not gained use in RCC diagnostics and prognosis prediction. Identification and evaluation of new molecular parameters are of utmost importance in cancer research and cancer treatment. Here we present a novel approach to rapidly identify clinically relevant molecular changes in cancer. To identify genes with relevance to RCC, a cDNA array analysis was first performed on 5184 cDNA clones on a filter to screen for genes with differential expression between the renal cancer cell line CRL-1933 and normal kidney tissue. There were 89 differentially expressed genes in the cancer cell line, one of them coding for vimentin, a cytoplasmic intermediate filament. In a second step, a renal cancer tissue microarray containing 532 RCC specimen was used to determine vimentin expression by immunohistochemistry. Vimentin expression was seen frequently in clear cell (51%) and papillary RCC (61%), but rarely in chromophobe RCC (4%) and oncocytomas (12%). Furthermore, vimentin expression was significantly associated with poor patient prognosis (P < 0.007) independent of grade and stage. These results obtained from minute arrayed tumor samples match well with previous findings on vimentin expression in renal tumors. It is concluded that the combination of tumor arrays and cDNA arrays is a powerful approach to rapidly identify and further evaluate genes that play a role in tumor biology.
许多基因和信号通路参与肾细胞癌(RCC)的发生发展。然而,基因肿瘤标志物尚未应用于RCC的诊断和预后预测。鉴定和评估新的分子参数在癌症研究和癌症治疗中至关重要。在此,我们提出一种新方法,可快速鉴定癌症中与临床相关的分子变化。为了鉴定与RCC相关的基因,首先对滤膜上的5184个cDNA克隆进行cDNA阵列分析,以筛选在肾癌细胞系CRL-1933和正常肾组织之间差异表达的基因。癌细胞系中有89个差异表达基因,其中一个编码波形蛋白,一种细胞质中间丝。第二步,使用包含532个RCC标本的肾癌细胞组织微阵列通过免疫组织化学确定波形蛋白的表达。波形蛋白表达在透明细胞癌(51%)和乳头状RCC(61%)中常见,但在嫌色细胞癌(4%)和嗜酸细胞瘤(12%)中少见。此外,波形蛋白表达与患者预后不良显著相关(P < 0.007),且与分级和分期无关。从微小阵列肿瘤样本获得的这些结果与先前关于肾肿瘤中波形蛋白表达的研究结果非常吻合。结论是,肿瘤阵列和cDNA阵列的结合是一种强大的方法,可快速鉴定并进一步评估在肿瘤生物学中起作用的基因。